Early administered antibiotics do not impact mortality in critically ill patients with COVID-19.

  11 June 2020

COVID-19 may mimic bacterial pneumonia and, therefore, antibiotics for possible bacterial coinfection were frequently administered. We conducted a retrospective analysis aimed at describing the impact of early antibiotic therapy (i.e., before intensive care unit [ICU] admission) on mortality and delayed severe healthcare-associated infections in the ICU.

However, our preliminary results illustrate that early administered antibiotics do not appear to significantly impact mortality or delayed hospital-acquired infections in critically ill patients and call into question the utility of early treatment of a presumptive bacterial superinfection in COVID-19 patients. Large multi-centric studies are urgently needed to investigate the impact of early antibiotics therapy on mortality, subsequent healthcare associated infections and ICU complications (i.e., duration of mechanical ventilation).

Further reading: Journal of Infection
Author(s): Niccolò Buetti, MDMSc Timothy Mazzuchelli Elia Lo Priore, MD Pierpaolo Trimboli, MDProf Valentina Forni-Ogna, MD Enos Bernasconi, MDProf et al
Effective Surveillance   Healthy Patients  


Unrestricted financial support by:


Antimicrobial Resistance Fighter Coalition

Bangalore Bioinnovation Centre


Global Ambassador Network

Welcome at the AMR Insights Ambassador Network!

The AMR Insights Ambassador Network is a growing, distinctive group of professionals who stand out for their commitment, willingness to cooperate and open attitude to combat Antimicrobial resistance (AMR).

More information and free-of-charge registration
What is going on with AMR?
Stay tuned with remarkable global AMR news and developments!